These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10963001)

  • 1. [High-dose chemotherapy for metastatic breast cancer without certain advantages so far].
    Kleeberg UR
    Strahlenther Onkol; 2000 Jul; 176(7):334-5. PubMed ID: 10963001
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of anti-oestrogen Zitazonium (tamoxifen) as adjuvant to cytostatic treatment in metastatic breast cancer.
    Palka I; Jávor J
    Ther Hung; 1986; 34(4):217-23. PubMed ID: 3449976
    [No Abstract]   [Full Text] [Related]  

  • 4. [Chemotherapy of disseminated forms of breast cancer using platinum derivatives].
    Gorbunova VA; Trofimova NB; Manziuk LV
    Vopr Onkol; 1990; 36(4):455-7. PubMed ID: 2345995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
    Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
    Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
    Petru E; Schmähl D
    Wien Klin Wochenschr; 1986 Dec; 98(23):790-7. PubMed ID: 3811371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combined chemotherapy in metastatic breast cancer: predictive value of dose levels and performance status].
    Brufman G; Sulkes A; Fuks Z; Biran S
    Harefuah; 1986 Jul; 111(1-2):24-6. PubMed ID: 3781373
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chemotherapy of metastasizing breast cancer].
    Wascher H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):590-4. PubMed ID: 3841627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sequential combination chemotherapy in metastatic cancer of the breast].
    Leone BA; Rabinovich MG; Strauss E; Arévalo E
    Medicina (B Aires); 1984; 44(1):15-22. PubMed ID: 6549523
    [No Abstract]   [Full Text] [Related]  

  • 13. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
    J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy combining vindesine, thiotepa and methotrexate in metastatic breast cancer after failure of a combination containing anthracycline. Results of a prospective phase II trial].
    Comoz M; Chevallier B; Bastit P
    Bull Cancer; 1988; 75(3):281-3. PubMed ID: 3130910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old school regimen may turn the tide in metastatic breast cancer.
    Gezgen G; Roach EC; Kizilarslanoglu MC; Altundag K
    J BUON; 2011; 16(4):781. PubMed ID: 22331741
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of mitoxantrone in the treatment of breast cancer.
    Hainsworth JD
    Semin Oncol; 1995 Feb; 22(1 Suppl 1):17-20. PubMed ID: 7863347
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.
    Livingston R; Crowley J
    J Clin Oncol; 1999 Nov; 17(11 Suppl):22-4. PubMed ID: 10630257
    [No Abstract]   [Full Text] [Related]  

  • 20. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
    Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
    Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.